Savolitinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Savolitinib
Accession Number
DB12048
Description

Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 345.37
Monoisotopic: 345.145041519
Chemical Formula
C17H15N9
Synonyms
  • Volitinib
External IDs
  • AZD6094
  • HMPL-504

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Savolitinib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Savolitinib.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Savolitinib.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Savolitinib.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Savolitinib.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Savolitinib.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Savolitinib.
MethimazoleThe therapeutic efficacy of Methimazole can be decreased when used in combination with Savolitinib.
Parathyroid hormoneThe therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Savolitinib.
Potassium IodideThe therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Savolitinib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as imidazopyridines. These are organic polycyclic compounds containing an imidazole ring fused to a pyridine ring. Imidazole is 5-membered ring consisting of three carbon atoms, and two nitrogen centers at the 1- and 3-positions. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyridines
Sub Class
Not Available
Direct Parent
Imidazopyridines
Alternative Parents
Imidazo[1,2-a]pyridines / Pyridines and derivatives / Pyrazines / N-substituted imidazoles / Triazoles / Pyrazoles / Heteroaromatic compounds / Azacyclic compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
1,2,3-triazole / Aromatic heteropolycyclic compound / Azacycle / Azole / Heteroaromatic compound / Hydrocarbon derivative / Imidazo[1,2-a]pyridine / Imidazole / Imidazopyridine / N-substituted imidazole
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
2A2DA6857R
CAS number
1313725-88-0
InChI Key
XYDNMOZJKOGZLS-NSHDSACASA-N
InChI
InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
IUPAC Name
4-{1-[(1S)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1H-pyrazole
SMILES
C[[email protected]](N1N=NC2=NC=C(N=C12)C1=CN(C)N=C1)C1=CN2C=CN=C2C=C1

References

General References
Not Available
PubChem Compound
68289010
PubChem Substance
347828359
ChemSpider
34501055
BindingDB
50023342
ChEMBL
CHEMBL3334567
ZINC
ZINC000149738712
PDBe Ligand
V0L
Wikipedia
Savolitinib
PDB Entries
5lbw / 6sde

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentCarcinoma NOS / Enzyme Inhibitors / Kidney Diseases / Neoplasms by Site / Neoplasms, Kidney / Protein Kinase Inhibitors / Renal Cell Adenocarcinoma / Urologic Neoplasms1
2Active Not RecruitingTreatmentLocally Advanced Papillary Renal Cell Carcinoma / Metastatic Papillary Renal Cell Carcinoma / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer AJCC V7 / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Unresectable Renal Cell Carcinoma1
2Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced Gastric Adenocarcinoma1
2CompletedTreatmentPapillary Renal Cell Cancer1
2RecruitingTreatmentAdvanced Gastric Adenocarcinoma1
2RecruitingTreatmentCarcinoma NOS1
2RecruitingTreatmentCarcinoma, Colorectal / Metastatic Colon Adenocarcinoma / Metastatic Rectal Adenocarcinoma / Stage III Colon Cancer AJCC v8 / Stage III Rectal Cancer AJCC v8 / Stage IIIA Colon Cancer AJCC v8 / Stage IIIA Rectal Cancer AJCC v8 / Stage IIIB Colon Cancer AJCC v8 / Stage IIIB Rectal Cancer AJCC v8 / Stage IIIC Colon Cancer AJCC v8 / Stage IIIC Rectal Cancer AJCC v8 / Stage IV Colon Cancer AJCC v8 / Stage IV Rectal Cancer AJCC v8 / Stage IVA Colon Cancer AJCC v8 / Stage IVA Rectal Cancer AJCC v8 / Stage IVB Colon Cancer AJCC v8 / Stage IVB Rectal Cancer AJCC v8 / Stage IVC Colon Cancer AJCC v8 / Stage IVC Rectal Cancer AJCC v8 / Unresectable Colon Adenocarcinoma / Unresectable Rectal Adenocarcinoma1
2RecruitingTreatmentLung Sarcomatoid Carcinoma1
2RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.337 mg/mLALOGPS
logP1.88ALOGPS
logP1.07ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)6.67ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area91.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity119.06 m3·mol-1ChemAxon
Polarizability35.72 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 15:15 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates